Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

BD announced it would split from its biosciences and diagnostics unit, while Zimmer Biomet updated investors on its $1.1 ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Globus Medical expects the Nevro acquisition to be accretive to its earnings in the second year of operation. Globus Medical expects to report full financial results for 2024 and provide its updated ...

Globus Medical and Nevro Preliminary Full-Year 2024 Revenue Outlook: On January 8, 2025, Globus Medical announced preliminary 2024 net sales of $2.52 billion, an increase of 60.6% over prior year ...

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Globus Medical (NYSE:GMED) in the last three months. In the table below, you'll find a ...

Globus Medical has a 12 month low of $49.33 and a 12 month high of $94.93. Globus Medical ( NYSE:GMED – Get Free Report ) last issued its quarterly earnings data on Tuesday, November 5th.

Globus Medical (NYSE:GMED) said it has agreed to buy Nevro (NVRO) through an all-cash deal with an equity value of around $250M. Under the deal, Globus Medical (NYSE:GMED) will buy all of Nevro's ...

Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share.